Vortosiran for atrial fibrillation
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests a new drug called vortosiran for people with atrial fibrillation, an irregular heartbeat that can increase stroke risk. The study aims to see if the drug can help improve heart rhythm and reduce stroke risk while they continue taking blood thinners.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 45 years old
- You must have been diagnosed with atrial fibrillation within the last 12 months (confirmed by an ECG)
- You must be taking a blood thinner (DOAC) for at least 3 months to prevent strokes
- You must not have had a stroke or mini-stroke recently (within 14 days for stroke, 3 days for mini-stroke)
- You must not have severe kidney or liver disease
- Women who can still have children must use reliable birth control during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication to prevent strokes and blood clots in people with atrial fibrillation (an irregular heartbeat) who cannot safely take standard blood thinners. The drug works by blocking a different clotting factor, which may lower bleeding risks.
This trial looks at ways to help people with atrial fibrillation lower their risk of stroke, premature death, and worsening memory. It may help by identifying which prevention approach works best for a broader community of patients.
This trial tests two doses of rivaroxaban (15mg and 20mg) to see how well they prevent strokes in people with non-valvular atrial fibrillation, a type of irregular heartbeat not caused by a heart valve problem. It may be an option if you need blood thinners to lower your stroke risk.
This trial tests apixaban (a blood thinner) to prevent stroke in people with atrial fibrillation or atrial flutter who have very poor kidney function or are on dialysis. If you qualify, you may help researchers find a safer way to lower stroke risk for this higher-risk group.
This study tests the safety of a new blood thinner for people with atrial fibrillation (AFib) who need long-term stroke prevention. If you qualify, the study will compare this medication to standard anticoagulation therapy.
This study tests a new blood thinner to prevent strokes and blood clots in people with atrial fibrillation (a common heart rhythm problem). You may qualify if you have atrial fibrillation and at least one risk factor for stroke, or if you've never taken a blood thinner before.
Hear when a new Non-valvular Atrial Fibrillation (AF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.